The Genitourinary Cancers Program (GU) is a multidisciplinary research program that includes 17 members from 6 RPCI departments. The overall goal of the GU Program is to translate basic science findings into the clinical setting by identifying novel therapeutic targets and strategies for the prevention and treatment of patients with prostate, kidney and bladder cancer. There are three overarching themes for the GU Program: Theme 1: Genetic and epigenetic signatures;Theme 2: Tumor microenvironment;Theme 3: Novel therapeutic strategies. Program membership spans the breadth of genitourinary cancer and studies highlight investigations on the androgen receptor in prostate cancer, cellular targets in endothelial cells and tumor stem cells in prostate and kidney cancer, new target identification by genetic and epigenetic profiling in renal cell carcinoma and bladder cancer, and the role of vitamin D and broccoli sprout extracts in preclinical and clinical studies for therapy and prevention, respectively in bladder cancer. In addition, the program includes a robust portfolio of clinical studies based on research in the GU program. The GU Program is led by Roberto Pili MD, who has expertise in translational and clinical research in GU malignancies. Dr. Pili's leadership efforts focus on translating novel therapeutic strategies based on preclinical models of prostate, kidney and bladder cancer into clinical testing. The strength of the translational capability of the GU Program is documented by the number of investigator-initiated clinical trials (14) currently accruing across the three disease types. Since the last submission, GU members have authored 365 publications;19% inter-programmatic collaboration, and 32% intra-programmatic. Current annual total peer-reviewed Program funding is $10.3M, of which $9.0M is NCI, and the total extramural research funding is $11.9M. Weekly seminars, annual research retreats and symposiums foster internal and external collaborations. GU Program members use 13 of the 14 CCSG shared resources and their laboratories contribute to the mentoring of more than twenty pre-doctoral and post-doctoral students from the RPCI Graduate Division. Future plans include expanding the genetic and epigenetic characterization of drug resistant phenotypes across genitourinary cancers and developing novel multimodality, rational combination strategies for the treatment of prostate, kidney and bladder cancer.

Public Health Relevance

of the GU Program mission stems from the strong translational emphasis of all the research projects focused on the identification and testing of new therapies for the prevention and treatment of prostate, kidney and bladder cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738363
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$19,598
Indirect Cost
$7,752
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5
Liu, Song; Kumari, Sangeeta; Hu, Qiang et al. (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:
Wintrob, Zachary A P; Hammel, Jeffrey P; Nimako, George K et al. (2017) Insulin use, hormone receptor status and hematopoietic cytokines? circulation in women with diabetes mellitus and breast cancer. Data Brief 11:382-390
Danaher, Patrick; Warren, Sarah; Dennis, Lucas et al. (2017) Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer 5:18
Oakley, Emily; Bellnier, David A; Hutson, Alan et al. (2017) Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer. Lasers Surg Med 49:599-608
Espinal, Allyson C; Buas, Matthew F; Wang, Dan et al. (2017) FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women? Breast Cancer Res Treat 166:559-568
Moore, Kathleen N; Tritchler, David; Kaufman, Kenneth M et al. (2017) Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 147:396-401
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Gage-Bouchard, Elizabeth A (2017) Social support, flexible resources, and health care navigation. Soc Sci Med 190:111-118
Pol, Suyog U; Polanco, Jessie J; Seidman, Richard A et al. (2017) Network-Based Genomic Analysis of Human Oligodendrocyte Progenitor Differentiation. Stem Cell Reports 9:710-723

Showing the most recent 10 out of 1391 publications